Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.3199066HERBAGE HAVING A REFLECTIVE COATING
CA 23.02.2024
Int.Class A61K 9/72
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
72for smoking or inhaling
Appl.No 3199066 Applicant VAPOR OIL TECHNOLOGY LLC Inventor CAREY, CHAD ARTHUR
Herbage such as trimmed cannabis flowers have a reflective coating that sparkles and improves shelf life. The invention includes a first coating of a first cannabis plant extract including at least 60% -98% Tetrahydrocannabinol (THC) that forms a hardened layer on the dried herbage to mechanically preserve the shape of the herbage and enables handling and grinding of the herbage. A second coating of a second cannabis plant extract, including at least 90-99% Tetrahydrocannabinolic acid (THCa) forms crystals, or "diamonds", that are embedded in the first coating to improve aesthetics by reflecting light. The crystals improve shelf life by reducing absorption of light by the herbage. The weight sum of the combined coatings are in a particular ratio to the herbage. This ratio is between 1:4 and 2:1 on a weight to weight basis to cause the herbage to sparkle, to improve shelf life, and to enable grinding without sticking.
2.3199131CRYSTALLINE COATED HERBAGE HAVING A CONSISTENT CANNABINOID CONCENTRATION
CA 23.02.2024
Int.Class A61K 9/72
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
72for smoking or inhaling
Appl.No 3199131 Applicant VAPOR OIL TECHNOLOGY LLC Inventor CAREY, CHAD ARTHUR
Herbage such as cannabis flower having a thin coating including crystallized cannabinoids having an average diameter of less than 100 microns. The thin coating is in a ratio of no more than 1:10 on a weight to weight basis so that the total cannabinoid content of the herbage does not exceed 35% by weight. THCA crystals in the fonn of granules or powder to coat the herbage. In one embodiment, the herbage is heated to less than 100 degrees F to enable the coating to adhere. The coating improves structural integrity of the herbage so it resists crushing when transported or stacked in a container or during storage. The coating inhibits deleterious interactions between the herbage and ambient air while achieving a standardized THCtotai content.
3.20240058311USE OF SMO INHIBITOR IN PREPARATION OF DRUG FOR PREVENTING, DELAYING OR ALLEVIATING ACCESS STENOSIS OF ARTERIOVENOUS FISTULA
US 22.02.2024
Int.Class A61K 31/4355
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4355the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
Appl.No 18355219 Applicant JINAN UNIVERSITY Inventor Hui ZENG

Provided is use of a SMO inhibitor in the preparation of a drug for preventing, delaying or alleviating access stenosis of arteriovenous fistula. It is creatively found herein that a SMO inhibitor can protect endothelial cells under the stimulation of high glucose and alleviate endothelial cell dysfunction, and specifically reduce lactate dehydrogenase (LDH), reduce apoptosis and reduce the production of inflammatory cytokines TNF-α, MCP-1, and IL-6. Furthermore, it is found herein that the SMO inhibitor can improve endothelial cell dysfunction by increasing the blood flow velocity in blood vessels, increasing the inner diameter of the blood vessel, improving the vascular intima thickening and reducing the production of inflammatory cytokines, thereby achieving the purpose of preventing, delaying or alleviating the access stenosis of arteriovenous fistula.

4.102022121044Aufbereitungsanordnung
DE 22.02.2024
Int.Class A61K 35/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
Appl.No 102022121044 Applicant H & B Electronic GmbH & Co. KG Inventor Morlok Tobias

Eine Aufbereitungsanordnung (6) für ein von einem Patienten (P) entnommenes und nach Aufbereitung zu applizierendes Gewebematerial (G), wie insbesondere ein autologes Knorpel- oder Knochengewebe, weist einen Sammelbehälter (8), der eine Sammelaufnahme (34) zur Aufnahme des mittels einer Gewebeentnahmevorrichtung (12) entnommenen Gewebematerials (G) aufweist, einen Aufbereitungsbehälter (52), der eine Mischaufnahme (74) zur gemeinsamen Aufnahme des Gewebematerials (G) und eines flüssigen bis pastösen Mediums (M) aufweist, und eine Aufbereitungsvorrichtung (58) zur Vermischung des Gewebematerials (G) und des Mediums (M) auf. Dabei ist vorgesehen, dass eine Verbindungseinrichtung (50) vorgesehen ist, an der erste Befestigungsmittel (60) zur Anbringung des Sammelbehälters (8) und zweite Befestigungsmittel (66) zur Anbringung des Aufbereitungsbehälters (52) sowie eine zwischen der Sammelaufnahme (34) und der Mischaufnahme (74) positionierbare Durchtrittsöffnung (80) vorgesehen sind. embedded image

5.20240059698HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES
US 22.02.2024
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 18361062 Applicant Accutar Biotechnology Inc. Inventor Jie FAN

Disclosed are heteroaryl compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.

6.20240060070TREATMENT OF CANCER ASSOCIATED WITH VARIANT NOVEL OPEN READING FRAMES
US 22.02.2024
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 18267223 Applicant Cambridge Enterprise Limited Inventor Sudhakaran PRABAKARAN

The present application features methods of treating a cancer associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant leads to increased or reduced expression of the variant nORF.

7.20240058317LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS
US 22.02.2024
Int.Class A61K 31/4468
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4468having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
Appl.No 18489542 Applicant Amryt Pharmaceuticals Inc. Inventor Ruth NALLEN

Provided herein are methods of treating hyperlipidemia or hypercholesterolemia in pediatric patients with lomitapide or a pharmaceutically acceptable salt thereof.

8.20240058377PLASMONIC ENHANCED MAGNETIC NANOPARTICLES HYPERTHERMIA
US 22.02.2024
Int.Class A61K 33/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
26Iron; Compounds thereof
Appl.No 18500167 Applicant Board of Regents, The University of Texas System Inventor Ahmed El-Gendy

A method of plasmonic enhanced magnetic nanoparticles hyperthermia (PE-MNH) of M@X core/shell nanoparticles using laser energy. Up on laser exposure of the nanoparticles in solution, the plasmonic shell will heat up and isolate each particle in their own hydrodynamic shell that lead to reducing the inter-particle interaction of the magnetic nanoparticles. This will lead to disaggregated nanoparticle with high dispersity, free movement and rotation in solution as well as giant increase in SAR when the alternating magnetic field within clinical safety limits is applied. Application of this approach has the potential to revolutionize the current treatment regimens by replacing them with plasmonic enhanced magnetic nanoparticles hyperthermia therapy that is more effective, less toxic, and impact survival.

9.20240058380CORONA VIRUS-SPECIFIC T CELL RECEPTOR FUSION CONSTRUCTS, VECTORS ENCODING THE SAME, T CELLS COMPRISING THE SAME AND USES THEREOF
US 22.02.2024
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No 18032101 Applicant ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG Inventor Wolfgang SCHAMEL

The present invention is inter alma concerned with a T cell receptor fusion construct comprising two specific peptidic moieties, one of these two moieties binding to the spike protein from coro-naviruses and binding to ACE2, in particular the spike proteins from SARS-CoV-2 and/or SARS-CoV-1, and one of these moieties being a protein of the T cell receptor complex. A vector comprising the genetic information encoding the T cell receptor fusion construct is also part of the present invention, as well as a process of transfecting or transducing T cells and a modified T cell comprising the T cell receptor fusion construct. Importantly, the present invention also relates to a T cell receptor fusion construct, a vector or a modified T cell for use in the treatment of a disease and in particular for use in the treatment of a disease caused by a coronavirus such as e.g. COVID-19 or SARS.

10.20240058417AMELIORATION AND TREATMENT OF INFARCTION DAMAGE
US 22.02.2024
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 18167265 Applicant Bimyo GmbH Inventor Tienush Rassaf

Infarction damage is ameliorated or treated through the administration of a mitochondrial degradation inhibitor, such as one that acts by inhibiting translocation of one or more molecules across a mitochondrial membrane, for example BAX/BNIP3 complexes involved in mitochondrial degradation. By preventing mitochondrial degradation, one allows more efficient oxygenation of an infarcted region, allowing for a greater degree of cell survival and a more successful recovery.